3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street expectations. Revenue for Cabometyx soared. Exelixis even emerged from the period without a penny of debt.
Despite all of this good news, Exelixis shares fell on Thursday after the company announced its second-quarter results late Wednesday. Still, though, the stock is up more than 70% so far in 2017. Should investors move on after the biotech's big run-up and solid quarterly update? I'll be the first to admit that I've been leery of just how much the stock can keep up the momentum. However, I think Exelixis remains a stock to buy for the long run. Here are three reasons why.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.
